Regenera set to begin Singapore trials

By Melissa Trudinger
Tuesday, 03 August, 2004

Regenera (ASX: RGA) has received ethics committee approval to begin Phase III human clinical trials for its synthetic steroid drug Visagen at the Singapore Eye Research Institute.

The initial trial will test the treatment on cystoid macular oedema, and the company plans to expand the study with trials evaluating the therapy in age related macular degeneration, uveitis, diabetic macular oedema and as a co-treatment with photodynamic therapy.

Related News

Preventing neural graft rejection in Parkinson's patients

Researchers have engineered a way to fool the immune system into accepting neural grafts as part...

Retinal health linked to dementia risk, study shows

Researchers have discovered that the blood vessels at the back of the eye — called retinal...

Pancreatic cancer hijacks metabolism switch to help it spread

Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd